VTRS

Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for narcolepsy (type 1 and 2 – with and without cataplexy).

Viatris' Q2 showed better earnings quality, with adjusted net income and EPS up 11% while free cash flow doubled year-over-year. Deleveraging remains on track, while buybacks and dividends demonstrate that stronger cash generation is already supporting shareholder returns. Pipeline progress and new-product approvals provide additional growth optionality beyond the mature portfolio, with key Phase 3 assets approaching important milestones.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential upside of 318% from current share price of about 5.5 pence.

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Harrow Inc. (NASDAQ:HROW) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ:VTRS).

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.

Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago.